Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | CPN1 | P15169 | 4/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL15050063 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL4391659 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL28759471 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL15049946 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL1298202 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL51269 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL27699077 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL4398351 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL1675268 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11CPN1CPB2NOS2 | |
| Proline SCHEMBL7204958 | 0.94 | PTGS1 (0.46) | PTGS1SLC7A11CPN1CPB2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406494-B | Novel PD-L1 binding polypeptides for imaging | 百时美施贵宝公司 | 2022-03-25 | — | — | CN | disclosed |
| US-9205146-B2 | Compositions and methods for vaccinating against HSV-2 | VICAL INCORPORATED (US) | 2015-12-08 | — | — | US | disclosed |
| US-9161973-B2 | Compositions and methods for vaccinating against HSV-2 | VICAL INCORPORATED (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2521786-B1 | COMPOSITIONS FOR VACCINATING AGAINST HSV-2 | VICAL INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150030631-A1 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | VICAL INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150010597-A1 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | VICAL INCORPORATED (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150010596-A1 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | VICAL INCORPORATED (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140370055-A1 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | VICAL INCORPORATED (US) | 2014-12-18 | — | — | US | disclosed |
| US-8852610-B2 | Compositions and methods for vaccinating against HSV-2 | VICAL INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8852611-B2 | Compositions and methods for vaccinating against HSV-2 | VICAL INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-20080102087-A1 | positively charged liposome containing an expressible polynucleotide coding for an immunogenic peptide; polynucleotide operatively coding for a physiologically active form of either gD, VP11/12, VP13/14, VP22 or a combination thereof | VICAL, INCORPORATED (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080057080-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | VICAL INCORPORATED (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008011609-A2 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | VICAL INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070286869-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | VICAL INCORPORATED (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1766094-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | Vical Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060024670-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | VICAL INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2005116270-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | VICAL INCORPORATED (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1007532-A1 | OLIGONUCLEOTIDES FOR IDENTIFYING PRECURSORS OF AMIDATED POLYPEPTIDE HORMONES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010361-A1 | OLIGONUCLEOTIDES FOR IDENTIFYING PRECURSORS OF AMIDATED POLYPEPTIDE HORMONES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-03-04 | — | — | WO | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057080-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | UPF1, IRF3, RNGTT | PTGS1 3527/4885SLC7A11 4601/4885CPN1 478/4885 |
| US-20060024670-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | UPF1, IRF3, RNGTT | PTGS1 3527/4885SLC7A11 4601/4885CPN1 478/4885 |
| US-20070286869-A1 | Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection | UPF1, IRF3, RNGTT | PTGS1 3527/4885SLC7A11 4601/4885CPN1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.